Now showing items 1-2 of 2

  • Usmani, Saad Zafar; Schjesvold, Fredrik Hellem; Oriol, Albert; Karlin, Lionel; Cavo, Michele; Rifkin, Robert M.; Yimer, Habte Aragaw; LeBlanc, Richard; Takezako, Naoki; McCroskey, Robert Donald; Lim, Andrew Boon Ming; Suzuki, Kenshi; Kosugi, Hiroshi; Grigoriadis, George; Avivi, Irit; Facon, Thierry; Jagannath, Sundar; Lonial, Sagar; Ghori, Razi Uddin; Farooqui, Mohammed Z.H.; Marinello, Patricia; San-Miguel, Jesús (Journal article / Tidsskriftartikkel / AcceptedVersion; Peer reviewed, 2019)
    Background Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to improve treatment ...
  • Kaufman, Jonathan L.; Gasparetto, Cristina; Schjesvold, Fredrik H; Moreau, Philippe; Touzeau, Cyrille; Facon, Thierry; Boise, Lawrence H.; Jiang, Yanwen; Yang, Xiaoqing; Dunbar, Fengjiao; Vishwamitra, Deeksha; Unger, Stefanie; Macartney, Tammy; Pesko, John; Yu, Yao; Salem, Ahmed Hamed; Ross, Jeremy A.; Hong, Wan-Jen; Maciag, Paulo C.; Pauff, James M.; Kumar, Shaji (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
    Venetoclax (Ven) is a selective small‐molecule inhibitor of BCL‐2 that exhibits antitumoral activity against MM cells with t(11;14) translocation. We evaluated the safety and efficacy of Ven and dexamethasone (VenDex) ...